[ad_1]
Wedbush reiterated an “outperform” rating and issued a $90.00 price objective on shares of Apogee Therapeutics in a research report on Monday.
[ad_2]
Source link
Apogee Therapeutics' (APGE) Outperform Rating Reiterated at Wedbush
Related Posts
Digital Media Stocks To Research – August 23rd
[ad_1] Alibaba Group, Adobe, Rocket Companies, Sunrun, and Digital Realty Trust are the five Digital Media stocks to watch today,…
CVS Health subsidiary Omnicare files for Ch. 11 bankruptcy protection
[ad_1] CVS Health subsidiary Omnicare has filed for Chapter 11 bankruptcy protection two months after the long-term care business was…
CW Advisors LLC Has $1.37 Million Holdings in ASML Holding N.V. $ASML
[ad_1] CW Advisors LLC raised its position in ASML Holding N.V. (NASDAQ:ASML – Free Report) by 42.8% in the first…